Funding from the National Institute of Allergy and Infectious Diseases (NIAID) will expand Hesperos’ physiologically relevant Malaria-on-a-Chip model to bridge critical translational gaps and accelerate the evaluation of next-generation antimalarial therapies. ORLANDO, FLORIDA, 22 October 2026: … Read More
Featured on the cover of Advanced Science, our study presents a human-derived Malaria-on-a-Chip system that captures the biology of infection and delivers actionable insights for real-world therapeutic translation.
Hesperos and Oriental Yeast Co. form a strategic partnership to expand access to Human-on-a-Chip® services across Asia, accelerating safer, more effective preclinical drug development.
Hesperos and GalenusRx receive $3M NIH grant to study drug-induced dementia using Human-on-a-Chip® systems and improve medication safety for older adults.
PRESS RELEASE: Hesperos announces its Human-on-a-Chip® technology supported Dianthus Therapeutics’ FDA submission for a Phase II trial of DNTH103 for generalized myasthenia gravis.
The NIH has awarded Hesperos Inc. a $2 million dollar research grant to develop an advanced, animal free platform to test the potency of Botulinum Toxin (BoT).
In a recent study published in Biomaterials, a team of researchers led by Hesperos Chief Scientist Dr. J. Hickman established a significant finding to better understand ALS etiology and potential new treatment targets.
Dr. James J. Hickman elected as Fellow of the National Acadamy of Inventors Hesperos is excited to announce that Chief Scientist, Dr. James J. Hickman, has been elected fellow of the National Academy of Inventors (NAI). … Read More
Human-on-a-chip System for Use in Therapeutic Index Determination and Systemic Toxicity in Pre-clinical Drug Discovery Presented at AAPS 2020 by James J. Hickman, PhD Chief Scientist, Hesperos, Inc.
THE SCIENCE AND TECHNOLOGY PLATFORM THAT COULD